Aktienanalyse zu Niki BioSolutions, Inc. (NIKI)NIKINiki BioSolutions, Inc.

Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

Niki Biosolutions, Inc. is not a good buy right now due to its extremely low price and negative financial indicators. The current price is $1.60, which is significantly down from its 52-week high of $70.00, indicating a staggering 97.71% year-to-date decline. Additionally, the company has a negative PE ratio of -1.35 and a current ratio of only 0.56, suggesting liquidity issues. The main risk is the company's ongoing losses, as it reported a net income loss of $613,995 in the most recent quarter.